The earnings call reflected strong growth in revenue and bookings, driven by software performance and strategic investments in AI and R&D. However, challenges such as timing-related softness in Tier 1 software, regulatory services softness, and geopolitical uncertainties were noted. Overall, the highlights outweigh the lowlights, indicating a positive sentiment.

Company Guidance -

Q3 2025

In the Certara Second Quarter 2025 earnings call, the company reported a revenue of $104.6 million, reflecting a year-over-year growth of 12%, with bookings totaling $112 million, marking a 13% increase from the previous year. The company's software revenue reached $46.7 million, growing by 22% on a reported basis, while services revenue was $57.9 million, a 5% increase. Certara reaffirmed its full-year guidance, projecting total revenue between $415 million and $425 million and adjusted EBITDA margins of 30% to 32%. The company highlighted the strength in its QSP services and Simcyp software, with second quarter bookings in services growing by 15%. Additionally, the company noted a significant regulatory milestone for its Simcyp software, which received European Medicines Agency qualification. Certara’s strategic investments in AI and biosimulation technologies, including the upcoming launch of CertaraIQ, indicate a continued focus on expanding its Model Informed Drug Development platform.

Revenue and Bookings Growth

Second quarter revenue of $104.6 million represented 12% year-over-year growth, while second quarter bookings of $112 million reflected 13% year-over-year growth.

Software Revenue Surge

Software revenue of $46.7 million grew 22% on a reported basis and 9% organically, led by strong growth from Simcyp in addition to $5.1 million of contribution from Chemaxon.

EMA Qualification for Simcyp

Certara is the first and only company to receive European Medicines Agency (EMA) qualification for a PBPK Modeling Platform, a significant milestone for biosimulation.

Growing QSP Services

Strength in biosimulation services bookings was driven by QSP and Simcyp services. QSP reached a significant milestone with the optimization of ISB 2001, resulting in a Fast Track designation for relapsed refractory myeloma patients.

Strong Financial Performance

Adjusted EBITDA for the second quarter of 2025 was $31.9 million, an increase from $26.3 million in the second quarter of 2024, with an adjusted EBITDA margin of 31%.

Investment in AI and R&D

Certara is increasing investment in R&D to create a next-generation AI-enabled Model Informed Drug Development (MIDD) platform, with new products like CertaraIQ expected to launch in the fourth quarter.

Certara (CERT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CERT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.11 / -	0.13	―	―	―
Aug 06, 2025	2025 (Q2)	0.10 / 0.07	0.07	0.00% (0.00)
May 05, 2025	2025 (Q1)	0.11 / 0.14	0.1	40.00% (+0.04)
Feb 26, 2025	2024 (Q4)	0.12 / 0.15	0.09	66.67% (+0.06)
Nov 06, 2024	2024 (Q3)	0.11 / 0.13	0.11	18.18% (+0.02)
Aug 06, 2024	2024 (Q2)	0.10 / 0.07	0.12	-41.67% (-0.05)
May 07, 2024	2024 (Q1)	0.10 / 0.10	0.12	-16.67% (-0.02)
Feb 29, 2024	2023 (Q4)	0.11 / 0.09	0.16	-43.75% (-0.07)
Nov 08, 2023	2023 (Q3)	0.11 / 0.11	0.1	10.00% (<+0.01)
Aug 09, 2023	2023 (Q2)	0.13 / 0.12	0.09	33.33% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CERT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$9.53	$11.26	+18.15%
May 05, 2025	$12.78	$11.37	-11.03%
Feb 26, 2025	$12.33	$12.40	+0.57%
Nov 06, 2024	$10.91	$10.99	+0.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Certara, Inc. (CERT) report earnings?

Certara, Inc. (CERT) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Certara, Inc. (CERT) earnings time?

Certara, Inc. (CERT) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CERT EPS forecast?

CERT EPS forecast for the fiscal quarter 2025 (Q3) is 0.11.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing